Brii Bio Announces Topline End-of-Treatment Data from Phase 2b ENRICH and ENHANCE Studies for the Treatment of Chronic Hepatitis B
PR Newswire
DURHAM, N.C. and BEIJING, July 2, 2026
End-of-treatment data from ENRICH demonstrated higher HBsAg loss rates, consistent with ENSURE Cohort 4, confirming the role of BRII-179 in priming immune responses for functional cure strategiesEnd-of-treatment data from ENHANCE did not demonstrate improved HBsAg loss rates compared to ENSURE Cohorts 2 and 3, informing selection of combination regimen going forwardAs previously disclosed, advancement of ENRICH into Phase 3 remains subject to the outcome of arbitration with Vir Biotechnology regarding the elebsiran manufacturing technology transfer DURHAM, N.C. and BEIJING, July 2, 2026 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical need, today announced end-of-treatment (EOT) results from its ongoing Phase 2b ENRICH and ENHANCE studies investigating sequential versus concurrent combination regimens of BRII-179 with elebsiran and PEG-IFNα for chronic hepatitis B virus (HBV) infection.
